Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Syed Ikmal, Sharifah Intan Qhadijah ^a   Zaman Huri, Hasniza ^a,b   Vethakkan, Shireene Ratna ^a   Wan Ahmad, Wan Azman ^a,b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD36 ANTIGEN; CHEMERIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; HAPTOGLOBIN; HYDROXYBUTYRIC ACID; INSULIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LECTIN; LIVER X RECEPTOR; OROSOMUCOID; PLASMINOGEN ACTIVATOR INHIBITOR; RESISTIN; RETINOL BINDING PROTEIN 4; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ATHEROSCLEROSIS; COMORBIDITY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FIBRIN FORMATION; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; IMMUNOREGULATION; INSULIN METABOLISM; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 84887423821     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/698567     Document Type: Review

References (79)

1. Shaw J. E., Sicree R. A., Zimmet P. Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 2010 87 1 4 14 2-s2.0-73749083481 10.1016/j.diabres.2009.10.007
2. Roglic G., Unwin N., Mortality attributable to diabetes: estimates for the year 2010. Diabetes Research and Clinical Practice 2010 87 1 15 19 2-s2.0-73749086904 10.1016/j.diabres.2009.10.006
3. Stumvoll M., Goldstein B. J., van Haeften T. W., Type 2 diabetes: principles of pathogenesis and therapy. The Lancet 2005 365 9467 1333 1346 2-s2.0-17044386953 10.1016/S0140-6736(05)61032-X
4. American Diabetes Association, Prevention and Management of Diabetes Complications 2013 Alexandria, Va, USA American Diabetes Association
5. American Diabetes Association, Prevention and Management of Diabetes Complications 2012 Alexandria, Va, USA American Diabetes Association
6. Marian R., Daniel Z., Ralph D., Steven H., Mohammed F. S., Joev S., Richard B., Peter S., Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis study. Diabetes Care 2004 27 3 781 787 2-s2.0-1442275321 10.2337/diacare.27.3.781 (Pubitemid 38280550)
7. American Heart Association,. http://www.heart.org/HEARTORG/Conditions/ More/MyHeartandStrokeNews/Coronary-Artery-Disease-The-ABCs-ofCAD-UCM-436416- Article.jsp
8. Lebovitz H. E., Type 2 diabetes: an overview. Clinical Chemistry 1999 45 8 1339 1345 2-s2.0-0032877903 (Pubitemid 29422073)
9. Libby P., Inflammation in atherosclerosis. Nature 2002 420 6917 868 874 2-s2.0-0037180771 10.1038/nature01323 (Pubitemid 36019640)
10. Reaven G., The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinology and Metabolism Clinics of North America 2004 33 supplement 2 283 303 2-s2.0-2542424815 10.1016/j.ecl.2004.03.002 (Pubitemid 38680631)
11. Alaa B., Amira K., Pierre H., David E. C. C., Bibiana G. B., Ahmed E., Mohamed K., Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk nd nutritional intervention. Diabetes, Metabolic Syndrome and Obesity 2010 3 173 186
12. Sjoholm A., Nystrom T., Inflammation and the etiology of type 2 diabetes. Diabetes/Metabolism Research and Reviews 2006 22 4 10 (Pubitemid 43154455)
13. Endemann D. H., Schiffrin E. L., Endothelial dysfunction. Journal of the American Society of Nephrology 2004 15 8 1983 1992 2-s2.0-3543133645 10.1097/01.ASN.0000132474.50966.DA (Pubitemid 39031337)
14. Willa A. H., Manuel J. Q., Role of endothelial dysfunction in insulin resistance. The American Journal of Cardiology 2003 92 10 17 2-s2.0-0141723637
15. Rehli M., Niller H., Ammon C., Langmann S., Schwarzfischer L., Andreesen R., Krause S. W., Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. Journal of Biological Chemistry 2003 278 45 44058 44067 2-s2.0-0242498371 10.1074/jbc.M306792200 (Pubitemid 37377146)
16. Johansen J. S., Jensen B. V., Roslind A., Nielsen D., Price P. A., Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiology Biomarkers and Prevention 2006 15 2 194 202 2-s2.0-33644782522 10.1158/1055-9965.EPI-05-0011 (Pubitemid 43342164)
17. Roslind A., Johansen J. S., YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods in Molecular Biology 2009 511 159 184 2-s2.0-65549120037 10.1007/978-1-59745-447-6-7
18. Østergaard C., Johansen J. S., Benfield T., Price P. A., Lundgren J. D., YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clinical and Diagnostic Laboratory Immunology 2002 9 3 598 604 2-s2.0-0036113515 10.1128/CDLI.9.3.598-604.2002 (Pubitemid 34538220)
19. Nishikawa K. C., Millis A. J. T., gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Experimental Cell Research 2003 287 1 79 87 2-s2.0-0037530029 10.1016/S0014-4827(03)00069-7 (Pubitemid 36683203)
20. Rathcke C. N., Johansen J. S., Vestergaard H., YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflammation Research 2006 55 2 53 59 2-s2.0-33645815907 10.1007/s00011-005-0010-8
21. Rathcke C. N., Persson F., Tarnow L., Rossing P., Vestergaard H., YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009 32 2 323 328 2-s2.0-61849086267 10.2337/dc08-1144
22. Kyrgios I., Galli-Tsinopoulou A., Stylianou C., Papakonstantinou E., Arvanitidou M., Haidich A., Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Metabolism 2012 61 4 562 568 2-s2.0-84858446769 10.1016/j.metabol.2011.09.004
23. Walter E. G., Kirk B., Kay A. L., Klaus-Peter A., Matthew W. M., Pamela J. N., John A. R., Michael V. M., Monica N., Stefania C., Andrea N., Ele: F., α -hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 2010 5 supplement 5 11 2-s2.0-77956293821 10.1371/journal.pone.0010883 e10883
24. Rosalki S. B., Wilkinson J. H., Reduction of α -ketobutyrate by human serum. Nature 1960 188 4756 1110 1111 2-s2.0-0000903690 10.1038/1881110a0
25. Landaas S., The formation of 2 hydroxybutyric acid in experimental animals. Clinica Chimica Acta 1975 58 1 23 32 2-s2.0-0016423016 10.1016/0009-8981(75)90481-7
26. Silverstein R. L., Li W., Park Y. M., Rahaman S. O., Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Transactions of the American Clinical and Climatological Association 2010 121 206 220 2-s2.0-78650419300
27. Handberg A., Levin K., Højlund K., Beck-Nielsen H., Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation 2006 114 11 1169 1176 2-s2.0-33748667302 10.1161/CIRCULATIONAHA.106.626135 (Pubitemid 44386481)
28. Maximilliano J. J. D., Nengming X., Adam L. C., Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. PLoS ONE 2009 4 10 2-s2.0-70449580312 10.1371/journal.pone.0007411 e7411
29. Handberg A., Skjelland M., Annika E. M., Ellen L. S., Kirsten K., David R., Arve D., Thor U., Erik O., Pal A., Bente H., Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke 2008 39 11 3092 3095 2-s2.0-55749104215 10.1161/STROKEAHA.108.517128
30. Liang C., Han S., Okamoto H., Carnemolla R., Tabas I., Accili D., Tall A. R., Increased CD36 protein as a response to defective insulin signaling in macrophages. Journal of Clinical Investigation 2004 113 5 764 773 2-s2.0-1842591333 10.1172/JCI200419528 (Pubitemid 38544170)
31. Collot-Teixeira S., Martin J., McDermott-Roe C., Poston R., McGregor J. L., CD36 and macrophages in atherosclerosis. Cardiovascular Research 2007 75 3 468 477 2-s2.0-34447509398 10.1016/j.cardiores.2007.03.010 (Pubitemid 47080960)
32. Febbraio M., Silverstein R. L., CD36: implications in cardiovascular disease. International Journal of Biochemistry and Cell Biology 2007 39 11 2012 2030 2-s2.0-34548482011 10.1016/j.biocel.2007.03.012 (Pubitemid 47376825)
33. Podrez E. A., Byzova T. V., Febbraio M., Salomon R. G., Ma Y., Valiyaveettil M., Poliakov E., Sun M., Finton P. J., Curtis B. R., Chen J., Zhang R., Silverstein R. L., Hazen S. L., Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nature Medicine 2007 13 9 1086 1095 2-s2.0-34948882706 10.1038/nm1626 (Pubitemid 47517507)
34. Handberg A., Norberg M., Stenlund H., Hallmans G., Attermann J., Eriksson J. W., Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. Journal of Clinical Endocrinology and Metabolism 2010 95 4 1939 1946 2-s2.0-77951642621 10.1210/jc.2009-2002
35. van Dielen F. M. H., Van't Veer C., Schols A. M., Soeters P. B., Buurman W. A., Greve J. W. M., Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. International Journal of Obesity 2001 25 12 1759 1766 2-s2.0-0035209720 10.1038/sj.ijo.0801825 (Pubitemid 33131915)
36. Steppan C. M., Lazar M. A., Resistin and obesity-associated insulin resistance. Trends in Endocrinology and Metabolism 2002 13 1 18 23 2-s2.0-0036134187 10.1016/S1043-2760(01)00522-7 (Pubitemid 36734011)
37. Rajala M. W., Scherer P. E., Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003 144 9 3765 3773 2-s2.0-0042330251 10.1210/en.2003-0580 (Pubitemid 37088727)
38. Kang S. M., Kwon H. M., Hong B. K., Kim D., Kim I. J., Choi E. Y., Jang Y., Kim H. S., Kim M. S., Kwon H. C., Expression of leptin receptor (Ob-R) in human atherosclerotic lesions: potential role in intimal neovascularization. Yonsei Medical Journal 2000 41 1 68 75 2-s2.0-0034136240
39. Yamagishi S., Edelstein D., Du X., Kaneda Y., Guzmán M., Brownlee M., Leptin induces mitochondrial superoxide production and monocyte chemoattractantprotein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. Journal of Biological Chemistry 2001 276 27 25096 25100 2-s2.0-0035816639 10.1074/jbc.M007383200
40. Park H., Kwon H. M., Lim H. J., Hong B. K., Lee J. Y., Park B. E., Jang Y., Cho S. Y., Kim H., Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Experimental and Molecular Medicine 2001 33 2 95 102 2-s2.0-0035973147 (Pubitemid 32655888)
41. Parhami F., Tintut Y., Ballard A., Fogelman A. M., Demer L. L., Leptin enhances the calcification of vascular cells artery wall as a target of leptin. Circulation Research 2001 88 9 954 960 2-s2.0-0035844031 (Pubitemid 32441475)
42. Faggioni R., Feingold K. R., Grunfeld C., Leptin regulation of the immune response and the immunodeficiency of malnutrition. The FASEB Journal 2001 15 14 2565 2571 2-s2.0-0035195887 10.1096/fj.01-0431rev (Pubitemid 33131083)
43. Wallace A. M., McMahon A. D., Packard C. J., Kelly A., Shepherd J., Gaw A., Sattar N., Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001 104 25 3052 3056 2-s2.0-0035909997 (Pubitemid 34014056)
44. Mantzoros C. S., The role of leptin in human obesity and disease: a review of current evidence. Annals of Internal Medicine 1999 130 8 671 680 2-s2.0-0033586747 (Pubitemid 29196202)
45. Margetic S., Gazzola C., Pegg G. G., Hill R. A., Leptin: a review of its peripheral actions and interactions. International Journal of Obesity 2002 26 11 1407 1433 2-s2.0-0036866913 10.1038/sj.ijo.0802142 (Pubitemid 36007818)
46. Karatela R. A., Sainani G. S., Interrelationships of factor VII activity and plasma leptin with insulin resistance in coronary heart disease. Atherosclerosis 2010 209 1 235 240 2-s2.0-77049115183 10.1016/j.atherosclerosis. 2009.08.043
47. Patel L., Buckels A. C., Kinghorn I. J., Murdock P. R., Holbrook J. D., Plumpton C., Macphee C. H., Smith S. A., Resistin is expressed in human macrophages and directly regulated by PPAR γ activators. Biochemical and Biophysical Research Communications 2003 300 2 472 476 2-s2.0-0037427540 10.1016/S0006-291X(02)02841-3 (Pubitemid 38375833)
48. Banerjee R. R., Rangwala S. M., Shapiro J. S., Rich A. S., Rhoades B., Qi Y., Wang J., Rajala M. W., Pocai A., Scherer P. E., Steppan C. M., Ahima R. S., Obici S., Rossetti L., Lazar M. A., Regulation of fasted blood glucose by resistin. Science 2004 303 5661 1195 1198 2-s2.0-10744225368 10.1126/science.1092341 (Pubitemid 38233585)
49. Muse E. D., Obici S., Bhanot S., Monia B. P., McKay R. A., Rajala M. W., Scherer P. E., Rossetti L., Role of resistin in diet-induced hepatic insulin resistance. Journal of Clinical Investigation 2004 114 2 232 239 2-s2.0-4043082182 10.1172/JCI200421270 (Pubitemid 39071628)
50. Galic S., Oakhill J. S., Steinberg G. R., Adipose tissue as an endocrine organ. Molecular and Cellular Endocrinology 2010 316 2 129 139 2-s2.0-72449191699 10.1016/j.mce.2009.08.018
51. Zhang M. H., Na B., Schiller N. B., Whooley M. A., Association of resistin with heart failure and mortality in patients with stable coronary heart disease: data from the heart and soul study. Journal of Cardiac Failure 2011 17 1 24 30 2-s2.0-78650696324 10.1016/j.cardfail.2010.08.007
52. Miyamoto Y., Morisaki H., Kokubo Y., Yamanaka I., Tomoike H., Okayama A., Yoshimasa Y., Morisaki T., Resistin gene variations are associated with the metabolic syndrome in Japanese men. Obesity Research and Clinical Practice 2009 3 2 65 74 2-s2.0-63749120621 10.1016/j.orcp.2008.11.003
53. Burnett M. S., Devaney J. M., Adenika R. J., Lindsay R., Howard B. V., Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. Journal of Clinical Endocrinology and Metabolism 2006 91 supplement 1 64 68 2-s2.0-30344453371 10.1210/jc.2005-1653 (Pubitemid 43069119)
54. Youn B., Yu K., Park H. J., Lee N. S., Min S. S., Youn M. Y., Cho Y. M., Park Y. J., Kim S. Y., Lee H. K., Park K. S., Plasma resistin concentrations measured by enzyme- linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2004 89 1 150 156 2-s2.0-10744220840 10.1210/jc.2003-031121 (Pubitemid 38183874)
55. Chen B. H., Song Y., Ding E. L., Roberts C. K., Manson J. E., Rifai N., Buring J. E., Gaziano J. M., Liu S., Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009 32 2 329 334 2-s2.0-61849130650 10.2337/dc08-1625
56. Nolan K. F., Greaves D. R., Waldmann H., The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci. Genomics 1998 51 1 161 163 2-s2.0-0032126111 10.1006/geno.1998.5336 (Pubitemid 28373391)
57. Dinarello C. A., Novick D., Puren A. J., Fantuzzi G., Shapiro L., Mühl H., Yoon D., Reznikov L. L., Kim S., Rubinstein M., Overview of interleukin-18: more than an interferon- γ inducing factor. Journal of Leukocyte Biology 1998 63 6 658 664 2-s2.0-0031749136 (Pubitemid 28274825)
58. Kashiwamura S., Ueda H., Okamura H., Roles of interleukin-18 in tissue destruction and compensatory reactions. Journal of Immunotherapy 2002 25 supplement 1 S4 S11 2-s2.0-0036196335 10.1097/00002371-200203001-00002 (Pubitemid 34260752)
59. Lindegaard B., Hansen A. E., Pilegaard H., Keller P., Gerstoft J., Pedersen B. K., Adipose tissue expression of IL-18 and HIV-associated lipodystrophy. AIDS 2004 18 14 1956 1958 2-s2.0-4744362281 10.1097/00002030- 200409240-00013 (Pubitemid 39313213)
60. Blankenberg S., Luc G., Ducimetière P., Arveiler D., Ferrières J., Amouyel P., Evans A., Cambien F., Tiret L., Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003 108 20 2453 2459 2-s2.0-0345688077 10.1161/01.CIR.0000099509.76044.A2 (Pubitemid 37444405)
61. Gu Y., Kuida K., Tsutsui H., Ku G., Hsiao K., Fleming M. A., Hayashi N., Higashino K., Okamura H., Nakanishi K., Kurimoto M., Tanimoto T., Flavell R. A., Sato V., Harding M. W., Livingston D. J., Su M. S.-S., Activation of interferon- γ inducing factor mediated by interleukin-1 β converting enzyme. Science 1997 275 5297 206 209 2-s2.0-15644369352 10.1126/science.275. 5297.206 (Pubitemid 27034760)
62. Tsutsui H., Kayagaki N., Kuida K., Nakano H., Hayashi N., Takeda K., Matsui K., Kashiwamura S., Hada T., Akira S., Yagita H., Okamura H., Nakanishi K., Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999 11 3 359 367 2-s2.0-0033198677 10.1016/S1074-7613(00)80111-9 (Pubitemid 29463244)
63. Fantuzzi G., Dinarello C. A., Interleukin-18 and interleukin-1 β: two cytokine substrates for ICE (caspase-1). Journal of Clinical Immunology 1999 19 1 1 11 2-s2.0-0032909752 (Pubitemid 29113328)
64. Kato Z., Jee J., Shikano H., Mishima M., Ohki I., Ohnishi H., Li A., Hashimoto K., Matsukuma E., Omoya K., Yamamoto Y., Yoneda T., Hara T., Kondo N., Shirakawa M., The structure and binding mode of interleukin-18. Nature Structural Biology 2003 10 11 966 971 2-s2.0-0242407130 10.1038/nsb993 (Pubitemid 37386108)
65. Novick D., Schwartsburd B., Pinkus R., Suissa D., Belzer I., Sthoeger Z., Keane W. F., Chvatchko Y., Kim S., Fantuzzi G., Dinarello C. A., Rubinstein M., A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001 14 6 334 342 2-s2.0-0035927494 10.1006/cyto.2001.0914 (Pubitemid 32730474)
66. Oikawa Y., Shimada A., Kasuga A., Morimoto J., Osaki T., Tahara H., Miyazaki T., Tashiro F., Yamato E., Miyazaki J., Saruta T., Systemic administration of IL-18 promotes diabetes development in young non-obese diabetic mice. Journal of Immunology 2003 171 11 5865 5875 2-s2.0-10744221229 (Pubitemid 37467203)
67. Esposito K., Pontillo A., Ciotola M., Di Palo C., Grella E., Nicoletti G., Giugliano D., Weight loss reduces interleukin-18 levels in obese women. Journal of Clinical Endocrinology and Metabolism 2002 87 8 3864 3866 2-s2.0-0036348333 10.1210/jc.87.8.3864 (Pubitemid 34879540)
68. Fischer C. P., Perstrup L. B., Berntsen A., Eskildsen P., Pedersen B. K., Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clinical Immunology 2005 117 2 152 160 2-s2.0-26044457651 10.1016/j.clim.2005.07.008 (Pubitemid 41407725)
69. Yang Q., Graham T. E., Mody N., Preitner F., Peroni O. D., Zabolotny J. M., Kotani K., Quadro L., Kahn B. B., Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005 436 7049 356 362 2-s2.0-22944434929 10.1038/nature03711 (Pubitemid 41065039)
70. Young M. C., Youn B., Lee H., Lee N., Min S., Soo H. K., Hong K. L., Kyong S. P., Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006 29 11 2457 2461 2-s2.0-33845479911 10.2337/dc06-0360 (Pubitemid 44912252)
71. Gavi S., Stuart L. M., Kelly P., Melendez M. M., Mynarcik D. C., Gelato M. C., McNurlan M. A., Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2007 92 supplement 5 1886 1890 2-s2.0-34249860936 10.1210/jc.2006-1815 (Pubitemid 46997205)
72. Roh S., Song S., Choi K., Katoh K., Wittamer V., Parmentier M., Sasaki S., Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochemical and Biophysical Research Communications 2007 362 4 1013 1018 2-s2.0-34548572409 10.1016/j.bbrc.2007.08.104 (Pubitemid 47390675)
73. Ernst M. C., Sinal C. J., Chemerin: at the crossroads of inflammation and obesity. Trends in Endocrinology and Metabolism 2010 21 11 660 667 2-s2.0-78049314118 10.1016/j.tem.2010.08.001
74. Du X., Leung L. L. K., Proteolytic regulatory mechanism of chemerin bioactivity. Acta Biochimica et Biophysica Sinica 2009 41 12 973 979 2-s2.0-71949124476 10.1093/abbs/gmp091
75. Zabel B. A., Allen S. J., Kulig P., Allen J. A., Cichy J., Handel T. M., Butcher E. C., Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. Journal of Biological Chemistry 2005 280 41 34661 34666 2-s2.0-27144444137 10.1074/jbc.M504868200 (Pubitemid 41504597)
76. Aso Y., Matsumoto S., Fujiwara Y., Tayama K., Inukai T., Takemura Y., Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 2002 51 4 471 476 2-s2.0-0036117399 10.1053/meta.2002.31334 (Pubitemid 34406564)
77. Bozaoglu K., Bolton K., McMillan J., Zimmet P., Jowett J., Collier G., Walder K., Segal D., Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007 148 10 4687 4694 2-s2.0-34748817386 10.1210/en.2007-0175 (Pubitemid 47481514)
78. Johanna W., Markus N., Josef W., Michael F., Sabrina B., Reiner W., Stefan F., Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clinical Endocrinology 2010 72 3 342 348 2-s2.0-76649090026 10.1111/j.1365-2265.2009.03664.x
79. Stejskal D., Karpisek M., Hanulova Z., Svestak M., Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-a pilot study. Biomedical papers of the Medical Faculty of the University Palacký 2008 152 2 217 221 2-s2.0-62449203154